Online Q&A: Innovation and Access – ways to sustain and improve Health Outcomes
02 April 2014, with IFPMA’s and Eli Lilly’s John Lechleiter
3:00pm – 4:00pm, CEST 9:00am - 10:00am, EDT
Join us on April 2nd as we host an online Q&A with John Lechleiter - CEO of Eli Lilly and Company and President of IFPMA - focused on innovation and access: ways to sustain and improve health outcomes. We encourage those interested to submit questions via the form on the Global Health Progress page.
Global Health Progress and the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) are proud to host an hour-long, conversation focused on the promise of medical innovation for global health with John C. Lechleiter - Chairman, President and CEO of Eli Lilly and President of IFPMA.
Among international global health stakeholders, the research-based pharmaceutical industry is an essential and unique contributor by researching and developing innovative medicines and vaccines. Successes like the eradication of polio in India, dramatic improvements in cancer survival, and vaccine-related prevention of disease are testament to the impact that the pharmaceutical industry can have on health around the world. However, many challenges remain to sustain and improve health outcomes through pharmaceutical innovation.
Topics that will be addressed during the hour-long conversation include:
- changing how we drive innovation
- innovation for neglected and rare diseases
- the power of innovation-focused partnerships for global health
- sustaining innovation and access: role of incentives
- the different dimensions of value delivered by innovation
John Lechleiter biography
John C. Lechleiter, Ph.D., has served as president and chief executive officer of Eli Lilly and Company since April 1, 2008. He became the chairman of the board of directors on January 1, 2009. He began work at Lilly in 1979 as a senior organic chemist in process research and development. Prior to joining Lilly, Lechleiter attended Xavier University (Cincinnati, Ohio), where he earned a bachelor of science degree in chemistry in 1975, and Harvard University, where he earned master’s and doctoral degrees in organic chemistry in 1980. Lechleiter has received honorary doctorates from Marian University (Indianapolis, Indiana), the University of Indianapolis, the National University of Ireland, and Indiana University. Lechleiter is a member of the American Chemical Society and Business Roundtable. He serves on the board of the Pharmaceutical Research and Manufacturers of America (PhRMA), as president of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), as chairman of the U.S.-Japan Business Council, and on the boards of United Way Worldwide, Xavier University (Cincinnati, Ohio), the Life Sciences Foundation, and the Central Indiana Corporate Partnership. He also serves on the boards of Nike, Inc. and Ford Motor Company.
IFPMA 2014 Interview Series: Andrew Jenner’s Take on Value of Innovation
In this video, Andrew Jenner, IFPMA’s Executive Director, Corporate Strategy & Legal Affairs, gives the pharmaceutical industry perspective on innovation. Despite the growing scientific, intellectual property and regulatory challenges of the past decades, over 340 new drugs have been introduced since 2002 to treat different chronic and non-chronic diseases. This can be considered as a big success story. Watch the video to find out why.
Jenner’s take is essentially based on the value of innovation from two dimensions: clinical and economic. These two dimensions are well demonstrated in two recently launched studies in 2014: the first, carried out by Charles River Associates, Assessing the value of biopharmaceutical innovation in key therapy areas in middle-income countries. The latter is evidenced by WifOR’s “First steps towards measuring the economic footprint of the industry”. To find out more about our organization: www.ifpma.org